---
title: "Earnings: Highlights of Abbott Laboratories’ (ABT) Q4 2025 report"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273395008.md"
description: "Abbott Laboratories (NYSE: ABT) reported a 4% increase in Q4 FY25 sales, reaching $11.46 billion, with organic sales growth of 3%. The company expects 6.5% to 7.5% organic sales growth for FY26. Net earnings rose to $1.50 per share, up from $1.34 per share year-over-year. Projected adjusted earnings for FY26 are between $5.55 and $5.80 per share, reflecting 10% growth at the midpoint. CEO Robert Ford highlighted margin expansion and a productive product pipeline in 2025."
datetime: "2026-01-22T15:11:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273395008.md)
  - [en](https://longbridge.com/en/news/273395008.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273395008.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273395008.md) | [繁體中文](https://longbridge.com/zh-HK/news/273395008.md)


# Earnings: Highlights of Abbott Laboratories’ (ABT) Q4 2025 report

Medical device maker Abbott Laboratories (NYSE: ABT) on Thursday reported a 4% increase in sales for the fourth quarter of FY25. The company also issued its full-year 2026 guidance.

Sales increased 4.4% year-over-year to $11.46 billion in the fourth quarter, with a 3% growth in organic sales. For fiscal 2026, Abbott expects organic sales growth to be in the range of 6.5% to 7.5%.

Excluding special items, net earnings rose to $1.50 per share in the December quarter from $1.34 per share in the prior-year quarter. The company projects full-year adjusted earnings in the range of $5.55 per share to $5.80 per share, which reflects 10% growth at the midpoint

On a reported basis, net income was $1.78 billion or $1.01 per share in the fourth quarter, vs. $9.2 billion or $5.27 per share in Q4 2024.

_“In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future,”_ said Robert Ford, Abbott’s CEO.

The post Earnings: Highlights of Abbott Laboratories’ (ABT) Q4 2025 report first appeared on AlphaStreet.

### 相关股票

- [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-CN/quote/XHE.US.md)
- [Abbott Laboratories (ABT.US)](https://longbridge.com/zh-CN/quote/ABT.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-CN/quote/IHI.US.md)

## 相关资讯与研究

- [What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders](https://longbridge.com/zh-CN/news/281606975.md)
- [Wealthcare Advisory Partners LLC Purchases 17,102 Shares of Abbott Laboratories $ABT](https://longbridge.com/zh-CN/news/280907601.md)
- [Net Worth Advisory Group Acquires Shares of 10,905 Abbott Laboratories $ABT](https://longbridge.com/zh-CN/news/280874003.md)
- [This Leading Pharma Company Has Grown Its Dividend 70% Since 2020](https://longbridge.com/zh-CN/news/280815145.md)
- [Major Investor Quietly Ramps Up Stake in Vivos Therapeutics](https://longbridge.com/zh-CN/news/281596321.md)